医学
G蛋白偶联受体
药品
药物开发
抗体-药物偶联物
计算生物学
受体
生物信息学
药理学
癌症研究
抗体
生物
免疫学
单克隆抗体
内科学
作者
Peyton High,Kendra S. Carmon
出处
期刊:Cancer Letters
[Elsevier]
日期:2023-06-01
卷期号:564: 216191-216191
被引量:2
标识
DOI:10.1016/j.canlet.2023.216191
摘要
In recent years, antibody-drug conjugates (ADCs) have emerged as promising anti-cancer therapeutic agents with several having already received market approval for the treatment of solid tumor and hematological malignancies. As ADC technology continues to improve and the range of indications treatable by ADCs increases, the repertoire of target antigens has expanded and will undoubtedly continue to grow. G protein-coupled receptors (GPCRs) are well-characterized therapeutic targets implicated in many human pathologies, including cancer, and represent a promising emerging target of ADCs. In this review, we will discuss the past and present therapeutic targeting of GPCRs and describe ADCs as therapeutic modalities. Moreover, we will summarize the status of existing preclinical and clinical GPCR-targeted ADCs and address the potential of GPCRs as novel targets for future ADC development.
科研通智能强力驱动
Strongly Powered by AbleSci AI